Ever heard of Larazotide Acetate? Apparently there has been a study going on of a drug called Larazotide Acetate which was designed to prevent the immune system’s negative reaction to gluten.
As you can imagine, this could be pretty significant for those of us that suffer from celiac disease and follow a strict gluten-free diet, so I wanted to share some of the information I found from the study:
Results from the study showed that larazotide acetate is the first pharmacologic agent to prevent changes in blood mononuclear cell populations (specifically T-reg cells and B Cells) and other markers of immunological change associated with active celiac disease. This data suggests that larazotide acetate offers potential as a future treatment of celiac disease. Results from a second poster presented at ACG showed that larazotide acetate also inhibited the effect of inflammatory cytokines, including tumor necrosis factor (TNF-alpha) and interleukin (IL-4) on intestinal epithelial permeability, in vitro, further suggesting that the product offers potential as a future treatment for inflammatory bowel disease (IBD).
Larazotide Acetate is a novel, non-absorbed peptide currently being studied in Phase IIb trials for the treatment of celiac disease. Larazotide acetate has the potential to become the first approved medicine to treat celiac disease and has been granted “Fast Track” designation from the U.S. Food and Drug Administration (FDA) for this indication.
It sounds like the FDA is expediting this, so hopefully it will get a lot of attention once it reaches the testing phase. In the meantime, if I get any additional information, I will pass it along here so make sure you are subscribed to our feed.